Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation.
Cidofovir (CDV) (HPMPC) has potent in vitro and in vivo activity against human cytomegalovirus (HCMV), CDV diphosphate (CDVpp), the putative antiviral metabolite of CDV, is an inhibitor and an alternate substrate of HCMV DNA polymerase. CDV is incorporated with the correct complementation to dGMP in the template, and the incorporated CDV at the primer end is not excised by the 3'-to-5' exonuclease activity of HCMV DNA polymerase. The incorporation of a CDV molecule causes a decrease in the rate of DNA elongation for the addition of the second natural nucleotide from the singly incorporated CDV molecule. The reduction in the rate of DNA (36-mer) synthesis from an 18-mer by one incorporated CDV is 31% that of the control. However, the fidelity of HCMV DNA polymerase is maintained for the addition of the nucleotides following a single incorporated CDV molecule. The rate of DNA synthesis by HCMV DNA polymerase is drastically decreased after the incorporation of two consecutive CDV molecules; the incorporation of a third consecutive CDV molecule is not detectable. Incorporation of two CDV molecules separated by either one or two deoxynucleoside monophosphates (dAMP, dGMP, or dTMP) also drastically decreases the rate of DNA chain elongation by HCMV DNA polymerase. The rate of DNA synthesis decreases by 90% when a template which contains one internally incorporated CDV molecule is used. The inhibition by CDVpp of DNA synthesis by HCMV DNA polymerase and the inability of HCMV DNA polymerase to excise incorporated CDV from DNA may account for the potent and long-lasting anti-CMV activity of CDV.
Xiong
X
X
Department of Biochemistry and Virology, Gilead Sciences, Foster City, California 94404, USA.
Smith
J L
JL
Chen
M S
MS
D000998:Antiviral Agents / Q000378:metabolism* / Q000494:pharmacology; D000077404:Cidofovir; D003587:Cytomegalovirus / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D003596:Cytosine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D017931:DNA Primers; D004279:DNA, Viral / Q000096:biosynthesis* / Q000187:drug effects; D004259:DNA-Directed DNA Polymerase / Q000096:biosynthesis*; D006801:Humans; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000378:metabolism* / Q000494:pharmacology*; D013698:Templates, Genetic
D000998:Antiviral Agents; D017931:DNA Primers; D004279:DNA, Viral; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D004259:DNA-Directed DNA Polymerase; D000077404:Cidofovir